BD and Check-Points receive CE Mark for new bacteria screening test

BD and Check-Points have received European CE Mark approval for a new next-generation screening test for antibiotic-resistant bacteria.

The test is used to screen for drug-resistant carbapenemase-producing organisms on the fully-automated BD Max System, providing detection for the five most common carbapenemase genes in less than 2.5 hours, rather than 24 hours with traditional methods.

This provides the necessary information to implement proper infection control measures, with the new assay replacing an earlier version of the test from Check-Points with an offering that provides an improved workflow and an additional target.

It is estimated by 2050, as many as ten million people could die annually from antimicrobial resistance if no action is taken, meaning testing options of this kind will become a vital tool for the medical profession in the coming years.

Nikos Pavlidis, vice-president of molecular diagnostics and women's health for BD, said: "The launch of the BD Max Check-Points CPO assay is another example of BD's commitment to helping prevent and reduce the spread of healthcare-associated infections and support better antimicrobial stewardship."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.